Transforming growth factor beta-induced p.(L558P) variant is associated with autosomal dominant lattice corneal dystrophy type IV in a large cohort of Spanish patients.


Journal

Clinical & experimental ophthalmology
ISSN: 1442-9071
Titre abrégé: Clin Exp Ophthalmol
Pays: Australia
ID NLM: 100896531

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 27 12 2018
revised: 18 03 2019
accepted: 30 04 2019
pubmed: 6 5 2019
medline: 21 10 2020
entrez: 7 5 2019
Statut: ppublish

Résumé

Rare transforming growth factor beta-induced (TGFBI) gene variants are involved in autosomal dominant corneal dystrophies (CDs) with heterogeneous clinical features. The purpose of this study was to analyse TGFBI gene variants and genotype-phenotype correlations in a cohort affected by atypical stromal CD. Retrospective cohort study (from May 2014 to September 2017). Thirty-five individuals from 10 unrelated South European families presenting atypical lattice CD (LCD) were included. Corneal phenotypes were assessed by slit-lamp examination and optical coherence tomography (OCT). Contrast sensitivity was measured under mesopic conditions. Genomic DNA was obtained from blood samples, and all 17 TGFBI exons were screened for variants by Sanger sequencing. p.(L558P) variant of TGFBI gene. The p.(L558P) variant was identified in 22 members of the 10 families diagnosed with atypical LCD, characterized by late-onset and absence of recurrent erosion syndrome. OCT revealed punctiform deposits in the deep-mid stroma and normal anterior stroma. This variant was demonstrated to be transmitted with the disease according to autosomal dominant inheritance in most families. To the best of our knowledge, we describe a detailed clinical characterization of the largest CD cohort carrying the TGFBI p.(L558P) variant. We propose that the atypical phenotype of this recently reported alteration can be classified as a form of LCD type IV. The results show that OCT and anterior-posterior analysis of the stromal location of the opacities, along with a genetic analysis of TGFBI, are required to ensure accurate diagnosis and management of CDs.

Sections du résumé

IMPORTANCE OBJECTIVE
Rare transforming growth factor beta-induced (TGFBI) gene variants are involved in autosomal dominant corneal dystrophies (CDs) with heterogeneous clinical features.
BACKGROUND BACKGROUND
The purpose of this study was to analyse TGFBI gene variants and genotype-phenotype correlations in a cohort affected by atypical stromal CD.
DESIGN METHODS
Retrospective cohort study (from May 2014 to September 2017).
PARTICIPANTS METHODS
Thirty-five individuals from 10 unrelated South European families presenting atypical lattice CD (LCD) were included.
METHODS METHODS
Corneal phenotypes were assessed by slit-lamp examination and optical coherence tomography (OCT). Contrast sensitivity was measured under mesopic conditions. Genomic DNA was obtained from blood samples, and all 17 TGFBI exons were screened for variants by Sanger sequencing.
MAIN OUTCOME MEASURES METHODS
p.(L558P) variant of TGFBI gene.
RESULTS RESULTS
The p.(L558P) variant was identified in 22 members of the 10 families diagnosed with atypical LCD, characterized by late-onset and absence of recurrent erosion syndrome. OCT revealed punctiform deposits in the deep-mid stroma and normal anterior stroma. This variant was demonstrated to be transmitted with the disease according to autosomal dominant inheritance in most families.
CONCLUSIONS AND RELEVANCE CONCLUSIONS
To the best of our knowledge, we describe a detailed clinical characterization of the largest CD cohort carrying the TGFBI p.(L558P) variant. We propose that the atypical phenotype of this recently reported alteration can be classified as a form of LCD type IV. The results show that OCT and anterior-posterior analysis of the stromal location of the opacities, along with a genetic analysis of TGFBI, are required to ensure accurate diagnosis and management of CDs.

Identifiants

pubmed: 31056827
doi: 10.1111/ceo.13532
doi:

Substances chimiques

Extracellular Matrix Proteins 0
Transforming Growth Factor beta 0
betaIG-H3 protein 148710-76-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

871-880

Informations de copyright

© 2019 Royal Australian and New Zealand College of Ophthalmologists.

Références

Bron AJ. Genetics of the corneal dystrophies: what we have learned in the past twenty-five years. Cornea. 2000;19:699-711.
Klintworth GK. Corneal dystrophies. Orphanet J Rare Dis. 2009;4:7.
Munier FL, Korvatska E, Djemai A, et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet. 1997;15:247-251.
Weiss JS, Møller HU, Aldave AJ, et al. IC3D classification of corneal dystrophies-edition 2. Cornea. 2015;34:117-159.
Lakshminarayanan R, Chaurasia SS, Anandalakshmi V, et al. Clinical and genetic aspects of the TGFBI-associated corneal dystrophies. Ocul Surf. 2014;12:234-251.
Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol. 1992;11:511-522.
Escribano J, Hernando N, Ghosh S, Crabb J, Coca-Prados M. cDNA from human ocular ciliary epithelium homologous to beta ig-h3 is preferentially expressed as an extracellular protein in the corneal epithelium. J Cell Physiol. 1994;160:511-521.
Zinn K, McAllister L, Goodman CS. Sequence analysis and neuronal expression of fasciclin I in grasshopper and Drosophila. Cell. 1988;53:577-587.
Blanco-Marchite C, Sanchez-Sanchez F, Lopez-Sanchez E, Escribano J. R124C and R555W TGFBI mutations in Spanish families with autosomal-dominant corneal dystrophies. Mol Vis. 2007;13:1390-1396.
Ann LB, Abbouda A, Frausto RF, et al. Variant lattice corneal dystrophy associated with compound heterozygous mutations in the TGFBI gene. Br J Ophthalmol. 2017;101:509-513.
Huerva V, Velasco A, Sanchez MC, Matias-Guiu X. Role of BIGH3 R124H mutation in the diagnosis of Avellino corneal dystrophy. Eur J Ophthalmol. 2008;18:345-350.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073-1081.
Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
Pampukha VM, Kravchenko SA, Tereshchenko FA, Livshits LA, Drozhyna GI. Novel L558P mutation of the TGFBI gene found in Ukrainian families with atypical corneal dystrophy. Ophthalmologica. 2009;223:207-214.
Livshits L, Pampukha VM, Tereshchenko FA, Drozhyna GI. Gene symbol: TGFBI. Disease: corneal dystrophy, lattice type. Hum Genet. 2008;124:296-297.
Finley JK, Berkowitz D, Croll MN. The physiological significance of gerontoxon. Arch Ophthalmol. 1961;66:211-213.
Shields CL, Mashayekhi A, Shields JA, Racciato P. Disappearance of eyelid xanthelasma following oral simvastatin (Zocor). Br J Ophthalmol. 2005;89:639-640.
Scorcia V, Busin M, Lucisano A, Beltz J, Carta A, Scorcia G. Anterior segment optical coherence tomography-guided big-bubble technique. Ophthalmology. 2013;120:471-476.
Kojima Y, Inoue T, Hori Y, Maeda N, Nishida K. Unilateral variant of late-onset lattice corneal dystrophy with the Pro501Thr mutation in the TGFBI gene without deposits in the unaffected cornea using confocal microscopy. Cornea. 2013;32:1396-1398.
Hirano K, Hotta Y, Nakamura M, Fujiki K, Kanai A, Yamamoto N. Late-onset form of lattice corneal dystrophy caused by leu527Arg mutation of the TGFBI gene. Cornea. 2001;20:525-529.
Oldak M, Szaflik JP, Sciezynska A, et al. Late-onset lattice corneal dystrophy without typical lattice lines caused by a novel mutation in the TGFBI gene. Cornea. 2014;33:294-299.
Stewart H, Black GC, Donnai D, et al. A mutation within exon 14 of the TGFBI (BIGH3) gene on chromosome 5q31 causes an asymmetric, late-onset form of lattice corneal dystrophy. Ophthalmology. 1999;106:964-970.
Kawasaki S, Yagi H, Yamasaki K, Matsuda A, Takeda K, Kinoshita S. A novel mutation of the TGFBI gene causing a lattice corneal dystrophy with deep stromal involvement. Br J Ophthalmol. 2011;95:150-151.
Fujiki K, Hotta Y, Nakayasu K, et al. A new L527R mutation of the betaIGH3 gene in patients with lattice corneal dystrophy with deep stromal opacities. Hum Genet. 1998;103:286-289.
Correa-Gomez V, Villalvazo-Cordero L, Zenteno JC. The TGFBI A546D mutation causes an atypical type of lattice corneal dystrophy. Mol Vis. 2007;13:1695-1700.
Chakravarthi SV, Kannabiran C, Sridhar MS, Vemuganti GK. TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients. Invest Ophthalmol Vis Sci. 2005;46:121-125.
Munier FL, Frueh BE, Othenin-Girard P, et al. BIGH3 mutation spectrum in corneal dystrophies. Invest Ophthalmol Vis Sci. 2002;43:949-954.
Pampukha VN, Kravchenko SA, Tereshchenko F, Drozhzhina GI, Livshits LA. [TGFBI gene mutations in the Ukrainian patients with inherited corneal stromal dystrophies]. Genetika. 2008;44:1392-1396.
Dudakova L, Palos M, Jirsova K, Skalicka P, Dundr P, Liskova P. Novel TGFBI mutation p.(Leu558Arg) in a lattice corneal dystrophy patient. Ophthalmic Genet. 2016;37:473-474.
Courtney DG, Poulsen ET, Kennedy S, et al. Protein composition of TGFBI-R124C- and TGFBI-R555W-associated aggregates suggests multiple mechanisms leading to lattice and granular corneal dystrophy. Invest Ophthalmol Vis Sci. 2015;56:4653-4661.
Sørensen CS, Runager K, Scavenius C, et al. Fibril core of transforming growth factor beta-induced protein (TGFBIp) facilitates aggregation of corneal TGFBIp. Biochemistry. 2015;54:2943-2956.

Auteurs

Ezequiel Campos-Mollo (E)

Ophthalmology Department, Hospital Virgen de los Lirios, Alcoy, Spain.
Cooperative Research Network on Age-Related Ocular Pathology, Visual and Life Quality, Institute of Health Carlos III, Madrid, Spain.

Yago Varela-Conde (Y)

Ophthalmology Department, Hospital Universitario Río Hortega, Valladolid, Spain.

Pedro Arriola-Villalobos (P)

Cooperative Research Network on Age-Related Ocular Pathology, Visual and Life Quality, Institute of Health Carlos III, Madrid, Spain.
Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain.
Institute of Health Research, Hospital Clínico San Carlos, Madrid, Spain.

Rubén Cabrera-Beyrouti (R)

Ophthalmology Department, Hospital de Lluís Alcanyís, Alicante, Spain.

José-Manuel Benítez-Del-Castillo (JM)

Cooperative Research Network on Age-Related Ocular Pathology, Visual and Life Quality, Institute of Health Carlos III, Madrid, Spain.
Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain.
Institute of Health Research, Hospital Clínico San Carlos, Madrid, Spain.
Immunology, Ophthalmology and Otorhinolaryngology Department, Complutense University, Madrid, Spain.
Rementería Clinic, Madrid, Spain.

Miguel J Maldonado (MJ)

Cooperative Research Network on Age-Related Ocular Pathology, Visual and Life Quality, Institute of Health Carlos III, Madrid, Spain.
Institute of Applied Ophthalmobiology (IOBA-Eye Institute), University of Valladolid, Valladolid, Spain.

Julio Escribano (J)

Cooperative Research Network on Age-Related Ocular Pathology, Visual and Life Quality, Institute of Health Carlos III, Madrid, Spain.
Genetics Area, Faculty of Medicine/IDINE, University of Castilla-La Mancha, Albacete, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH